Related Experiment Video

Updated: Jan 3, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin

W J Duan1, P D Bi2, Y Ma1

  • 1Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, China.

Neoplasma
|November 29, 2019
PubMed

Insights

MicroRNA-512-3p (miR-512-3p) enhances breast cancer treatment sensitivity and reduces metastasis by targeting Livin. This microRNA (miRNA) shows promise as a therapeutic target for breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer (BCa) is a leading cause of cancer-related deaths in women.
  • MicroRNAs (miRNAs) are implicated in cancer development and drug resistance.
  • MiR-512-3p is known to be upregulated in breast cancer cells.

Purpose of the Study:

  • To investigate the role of miR-512-3p in breast cancer progression and chemosensitivity.
  • To identify the molecular targets of miR-512-3p in breast cancer cells.
  • To evaluate the therapeutic potential of miR-512-3p in preclinical models.

Main Methods:

  • Overexpression of miR-512-3p in MCF-7 breast cancer cells.
  • Analysis of tumor architecture, cell-cell contact, adhesion, and motility.
  • Luciferase reporter assays to confirm direct targeting of Livin's 3'UTR.
  • In vitro chemosensitivity assays with epirubicin, gemcitabine, and docetaxel.
  • In vivo tumor growth inhibition studies.

Main Results:

  • MiR-512-3p overexpression reorganized tumor architecture, affecting cell-cell contact, adhesion, and motility.
  • Induction of miR-512-3p enhanced chemosensitivity and decreased metastatic potential in BCa cells.
  • MiR-512-3p directly targets Livin, reducing its expression and inhibiting breast cancer cell growth and metastasis.
  • Overexpression of miR-512-3p increased sensitivity to epirubicin, gemcitabine, and docetaxel, and inhibited tumor growth in vivo.

Conclusions:

  • MiR-512-3p plays a significant role in regulating breast cancer tumorigenesis and drug resistance.
  • MiR-512-3p directly targets Livin, leading to decreased cell growth and metastasis.
  • MiR-512-3p represents a potential therapeutic target for improving breast cancer treatment outcomes.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

689

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K